caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Company profile
Ticker
CDNA
Exchange
Website
CEO
Peter Maag
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EXPRESSION DIAGNOSTICS INC, XDx, Inc.
SEC CIK
Corporate docs
Subsidiaries
CareDx AB • CareDx Lab Solutions, Inc. • CareDx Transplant Management, Inc. • CareDx Pty Ltd. • HLA Data Systems, LLC • MediGO, Inc. ...
CDNA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
25 Apr 24
8-K
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
16 Apr 24
8-K
CareDx Appoints Bryan Riggsbee to Its Board of Directors
11 Mar 24
POS AM
Prospectus update (post-effective amendment)
1 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
POSASR
Automatic shelf registration (post-effective amendment)
28 Feb 24
S-8
Registration of securities for employees
12 Jan 24
8-K
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
9 Jan 24
8-K
Departure of Directors or Certain Officers
22 Dec 23
Transcripts
CDNA
Earnings call transcript
2023 Q4
28 Feb 24
CDNA
Earnings call transcript
2023 Q3
8 Nov 23
CDNA
Earnings call transcript
2023 Q2
8 Aug 23
CDNA
Earnings call transcript
2023 Q1
10 May 23
CDNA
Earnings call transcript
2022 Q4
27 Feb 23
CDNA
Earnings call transcript
2022 Q3
4 Nov 22
CDNA
Earnings call transcript
2022 Q2
7 Aug 22
CDNA
Earnings call transcript
2022 Q1
6 May 22
CDNA
Earnings call transcript
2021 Q4
25 Feb 22
CDNA
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
3
John Walter Hanna JR
25 Apr 24
4
Abhishek Jain
22 Apr 24
4
Abhishek Jain
10 Apr 24
4/A
Abhishek Jain
9 Apr 24
4/A
Alexander L Johnson
9 Apr 24
4
Peter Maag
8 Apr 24
4
Michael Goldberg
8 Apr 24
SC 13G/A
ArrowMark Colorado Holdings LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
GAGNON SECURITIES LLC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm | 76.56 mm |
Cash burn (monthly) | 3.94 mm | 549.58 k | 9.59 mm | 8.32 mm | 3.39 mm | 235.17 k |
Cash used (since last report) | 27.11 mm | 3.79 mm | 66.08 mm | 57.31 mm | 23.37 mm | 1.62 mm |
Cash remaining | 49.45 mm | 72.78 mm | 10.48 mm | 19.25 mm | 53.19 mm | 74.94 mm |
Runway (months of cash) | 12.6 | 132.4 | 1.1 | 2.3 | 15.7 | 318.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 152 |
Opened positions | 17 |
Closed positions | 20 |
Increased positions | 51 |
Reduced positions | 62 |
13F shares | Current |
---|---|
Total value | 388.99 bn |
Total shares | 61.05 mm |
Total puts | 5.20 k |
Total calls | 8.10 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 6.68 mm | $46.76 bn |
BLK Blackrock | 5.38 mm | $37.65 bn |
Vanguard | 4.14 mm | $28.97 bn |
BLVGF Bellevue | 3.94 mm | $27.59 bn |
STT State Street | 3.71 mm | $25.96 bn |
Bellevue Asset Management | 3.17 mm | $0.00 |
CMTDF Sumitomo Mitsui Trust | 3.02 mm | $21.17 bn |
Nikko Asset Management Americas | 3.02 mm | $21.11 bn |
D. E. Shaw & Co. | 2.32 mm | $16.27 bn |
Gagnon Securities | 2.08 mm | $14.53 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Abhishek Jain | Common Stock | Payment of exercise | Dispose F | No | No | 8.07 | 323 | 2.61 k | 293,054 |
8 Apr 24 | Abhishek Jain | Common Stock | Payment of exercise | Dispose F | No | No | 9.53 | 235 | 2.24 k | 293,377 |
4 Apr 24 | Goldberg Michael | Common Stock | Grant | Acquire A | No | No | 0 | 3,686 | 0.00 | 124,702 |
4 Apr 24 | Peter Maag | Common Stock | Grant | Acquire A | No | No | 0 | 1,249 | 0.00 | 313,983 |
Press releases
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
19 Apr 24
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
16 Apr 24
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
9 Apr 24
CareDx to Participate in the Raymond James & Associates' 45th Annual Institutional Investors Conference
27 Feb 24
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
21 Feb 24